MD3386991T2 - Compuși policiclici ca inhibitori de tirozin kinază Bruton - Google Patents

Compuși policiclici ca inhibitori de tirozin kinază Bruton Download PDF

Info

Publication number
MD3386991T2
MD3386991T2 MDE20180978T MDE20180978T MD3386991T2 MD 3386991 T2 MD3386991 T2 MD 3386991T2 MD E20180978 T MDE20180978 T MD E20180978T MD E20180978 T MDE20180978 T MD E20180978T MD 3386991 T2 MD3386991 T2 MD 3386991T2
Authority
MD
Moldova
Prior art keywords
oxo
thia
dihydro
triazaacenaphthylene
carboxamide
Prior art date
Application number
MDE20180978T
Other languages
English (en)
Romanian (ro)
Inventor
Nidhi Arora
Genesis M Bacani
Joseph Kent Barbay
Scott D Bembenek
Min Cai
Wei Chen
Charlotte Pooley Deckhut
James P Edwards
Brahmananda Ghosh
Kevin Kreutter
Gang Li
Mark S Tichenor
Jennifer D Venable
Jianmei Wei
John J M Wiener
Yao Wu
Kun Xiao
Feihuang Zhang
Yaoping Zhu
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MD3386991T2 publication Critical patent/MD3386991T2/ro

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/16Peri-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MDE20180978T 2015-12-10 2016-12-09 Compuși policiclici ca inhibitori de tirozin kinază Bruton MD3386991T2 (ro)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562265836P 2015-12-10 2015-12-10
PCT/US2016/065954 WO2017100662A1 (en) 2015-12-10 2016-12-09 Polycyclic compounds as inhibitors of bruton's tyrosine kinase

Publications (1)

Publication Number Publication Date
MD3386991T2 true MD3386991T2 (ro) 2020-11-30

Family

ID=57681784

Family Applications (1)

Application Number Title Priority Date Filing Date
MDE20180978T MD3386991T2 (ro) 2015-12-10 2016-12-09 Compuși policiclici ca inhibitori de tirozin kinază Bruton

Country Status (30)

Country Link
US (5) US10717745B2 (enExample)
EP (2) EP3386991B1 (enExample)
JP (2) JP6835846B2 (enExample)
KR (1) KR102103395B1 (enExample)
CN (2) CN108884106A (enExample)
AR (1) AR107042A1 (enExample)
AU (1) AU2016366541B2 (enExample)
BR (1) BR112018011526B1 (enExample)
CA (1) CA3007990C (enExample)
CY (1) CY1123263T1 (enExample)
DK (1) DK3386991T3 (enExample)
EA (1) EA035168B1 (enExample)
ES (1) ES2805835T3 (enExample)
HR (1) HRP20201193T1 (enExample)
HU (1) HUE049502T2 (enExample)
IL (1) IL259863B (enExample)
JO (1) JO3794B1 (enExample)
LT (1) LT3386991T (enExample)
MA (2) MA53110A (enExample)
MD (1) MD3386991T2 (enExample)
ME (1) ME03803B (enExample)
MX (1) MX387590B (enExample)
PL (1) PL3386991T3 (enExample)
PT (1) PT3386991T (enExample)
RS (1) RS60604B1 (enExample)
SI (1) SI3386991T1 (enExample)
SM (1) SMT202000404T1 (enExample)
TW (1) TWI729047B (enExample)
UY (1) UY37015A (enExample)
WO (1) WO2017100662A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3793B1 (ar) 2015-12-10 2021-01-31 Janssen Pharmaceutica Nv مثبطات تيروزين كاينيز بروتون وأساليب استخدامها
JO3794B1 (ar) 2015-12-10 2021-01-31 Janssen Pharmaceutica Nv المركبات متعددة الحلقات كمثبطات لتيروزين كيناز بروتون
TWI795381B (zh) 2016-12-21 2023-03-11 比利時商健生藥品公司 作為malt1抑制劑之吡唑衍生物
EP3596087A1 (en) * 2017-03-15 2020-01-22 Janssen Sciences Ireland Unlimited Company Methods of selective aryl- and heteroaryl-nitrogen bond formation
CN108164397B (zh) * 2018-01-18 2020-11-13 暨南大学 一类邻苯二酚衍生物及其制备方法
EP4268898A3 (en) 2018-06-11 2024-01-17 Amgen Inc. Kras g12c inhibitors for treating cancer
US12404260B2 (en) 2019-04-11 2025-09-02 Janssen Pharmaceutica Nv Pyridine rings containing derivatives as MALT1 inhibitors
US20230094146A1 (en) * 2020-01-07 2023-03-30 Medshine Discovery Inc. Deuterated thienopyridine compound
EP4301365A1 (en) * 2021-03-03 2024-01-10 Janssen Pharmaceutica NV Combination therapy using a malt1 inhibitor and a btk inhibitor
WO2022254371A1 (en) 2021-06-04 2022-12-08 Janssen Pharmaceutica Nv Inhibitors of bruton's tyrosine kinase and methods of their use
MX2023015147A (es) 2021-06-30 2024-04-01 Janssen Pharmaceutica Nv Inhibidores de la tirosina quinasa de bruton y métodos de su uso.
AU2022326183A1 (en) 2021-08-09 2024-03-28 Janssen Pharmaceutica Nv Compositions for use in treating b-cell malignancies
KR20240148351A (ko) * 2022-02-18 2024-10-11 얀센 파마슈티카 엔브이 브루톤 티로신 키나제 억제제의 합성

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3112415A1 (de) 1981-03-28 1982-10-07 Dynamit Nobel Ag, 5210 Troisdorf Verfahren zur chlorierung von cyclischen amiden und cyclischen vinylogen amiden
US5430150A (en) 1992-12-16 1995-07-04 American Cyanamid Company Retroviral protease inhibitors
US5300478A (en) 1993-01-28 1994-04-05 Zeneca Limited Substituted fused pyrazolo compounds
EP1789055A4 (en) 2004-09-15 2009-11-11 Janssen Pharmaceutica Nv INHIBITORS OF THIAZOLOPYRIDINE KINASE
US7579356B2 (en) 2005-05-04 2009-08-25 Janssen Pharmaceutica Nv Thia-tetraazaacenaphthylene kinase inhibitors
WO2007019191A2 (en) 2005-08-08 2007-02-15 Janssen Pharmaceutica, N.V. Thiazolopyrimidine kinase inhibitors
WO2007092879A2 (en) * 2006-02-08 2007-08-16 Janssen Pharmaceutica, N.V. Substituted thiatriazaacenaphthylene-6-carbonitrile kinase inhibitors
DK2529622T3 (en) 2006-09-22 2018-05-07 Pharmacyclics Llc INHIBITORS OF BRUTON-TYROSINKINASE
US8598174B2 (en) * 2008-11-12 2013-12-03 Genetech, Inc. Pyridazinones, method of making, and method of use thereof
EP2471789B9 (en) * 2009-08-26 2015-03-25 Takeda Pharmaceutical Company Limited Fused heterocyclic ring derivative and use thereof
WO2011133609A2 (en) 2010-04-19 2011-10-27 The Translational Genomics Research Institute Methods and kits to predict therapeutic outcome of btk inhibitors
FR2978441A1 (fr) 2011-07-25 2013-02-01 Diverchim Nouveaux analogues de ceramides, leurs procedes de preparation et leurs applications dans les compositions pharmaceutiques et cosmetiques
AU2014230935A1 (en) 2013-03-15 2015-09-03 Janssen Pharmaceutica Nv Processes and intermediates for preparing a medicament
ES2678021T3 (es) * 2013-12-11 2018-08-08 Biogen Ma Inc. Compuestos de biarilo útiles para el tratamiento de enfermedades humanas en oncología, neurología e inmunología
JO3794B1 (ar) 2015-12-10 2021-01-31 Janssen Pharmaceutica Nv المركبات متعددة الحلقات كمثبطات لتيروزين كيناز بروتون
JO3793B1 (ar) 2015-12-10 2021-01-31 Janssen Pharmaceutica Nv مثبطات تيروزين كاينيز بروتون وأساليب استخدامها
WO2018103058A1 (en) 2016-12-09 2018-06-14 Janssen Pharmaceutica Nv Inhibitors of bruton's tyrosine kinase and methods of their use
WO2018103060A1 (en) 2016-12-09 2018-06-14 Janssen Pharmaceutica Nv Inhibitors of bruton's tyrosine kinase and methods of their use

Also Published As

Publication number Publication date
MA43409B1 (fr) 2020-10-28
BR112018011526B1 (pt) 2024-02-27
JP6835846B2 (ja) 2021-02-24
US20190276471A1 (en) 2019-09-12
LT3386991T (lt) 2020-08-25
US10934310B2 (en) 2021-03-02
AR107042A1 (es) 2018-03-14
ME03803B (me) 2021-04-20
CA3007990C (en) 2024-01-02
DK3386991T3 (da) 2020-07-13
HRP20201193T1 (hr) 2020-11-13
EP3386991B1 (en) 2020-06-03
PT3386991T (pt) 2020-08-18
HUE049502T2 (hu) 2020-09-28
KR102103395B1 (ko) 2020-04-23
EA035168B1 (ru) 2020-05-08
CN113121562B (zh) 2022-09-13
AU2016366541B2 (en) 2021-05-13
US20230097422A1 (en) 2023-03-30
US12065446B2 (en) 2024-08-20
CY1123263T1 (el) 2021-12-31
JO3794B1 (ar) 2021-01-31
ES2805835T3 (es) 2021-02-15
SMT202000404T1 (it) 2020-09-10
EA201891378A1 (ru) 2018-12-28
IL259863A (en) 2018-07-31
JP2021073286A (ja) 2021-05-13
NZ742484A (en) 2021-09-24
US11319329B2 (en) 2022-05-03
TW201734021A (zh) 2017-10-01
AU2016366541A1 (en) 2018-05-31
RS60604B1 (sr) 2020-08-31
US20210101910A1 (en) 2021-04-08
MX2018007075A (es) 2018-11-09
IL259863B (en) 2020-06-30
JP2018536686A (ja) 2018-12-13
CA3007990A1 (en) 2017-06-15
UY37015A (es) 2017-06-30
US10717745B2 (en) 2020-07-21
MX387590B (es) 2025-03-18
JP7072690B2 (ja) 2022-05-20
EP3719022A1 (en) 2020-10-07
WO2017100662A1 (en) 2017-06-15
CN108884106A (zh) 2018-11-23
EP3386991A1 (en) 2018-10-17
KR20180093974A (ko) 2018-08-22
TWI729047B (zh) 2021-06-01
BR112018011526A2 (pt) 2018-11-21
US20240383914A1 (en) 2024-11-21
SI3386991T1 (sl) 2020-08-31
MA53110A (fr) 2021-05-12
CN113121562A (zh) 2021-07-16
PL3386991T3 (pl) 2021-03-08
US20170283430A1 (en) 2017-10-05

Similar Documents

Publication Publication Date Title
US12065446B2 (en) Inhibitors of Bruton's tyrosine kinase and method of their use
US10822348B2 (en) Inhibitors of Bruton's tyrosine kinase and methods of their use
WO2018103060A1 (en) Inhibitors of bruton's tyrosine kinase and methods of their use
WO2018103058A1 (en) Inhibitors of bruton's tyrosine kinase and methods of their use
HK40038735A (en) Polycyclic compounds as inhibitors of bruton's tyrosine kinase
NZ742484B2 (en) Polycyclic compounds as inhibitors of bruton's tyrosine kinase
HK40052204A (en) Polycyclic compounds as inhibitors of bruton's tyrosine kinase
HK40052204B (en) Polycyclic compounds as inhibitors of bruton's tyrosine kinase
HK1262330B (en) Polycyclic compounds as inhibitors of bruton's tyrosine kinase
HK1262330A1 (en) Polycyclic compounds as inhibitors of bruton's tyrosine kinase